SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)George D. Demetri, Michael C. Heinrich, Jayesh Desai et al.|Journal of Clinical Oncology|2004Cited by 103
SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic gastrointestinal stromal tumor (GIST)George D. Demetri, Michael C. Heinrich, Jayesh Desai et al.|Journal of Clinical Oncology|2004Cited by 46
Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Jason L. Weirather et al.|Clinical Cancer Research|2024Cited by 35
Supplementary Figure 1 from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Michael J. Nathenson et al.|Unknown|2024Cited by 1
Data from Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft-tissue Sarcomas: Clinical Outcomes and Biological CorrelatesCandace L. Haddox, Suzanne George, Michael J. Nathenson et al.|Unknown|2024Cited by 1